Neutrophil-Lymphocyte Ratio as a Prognostic Marker for Lung Adenocarcinoma After Complete Resection

被引:38
作者
Takahashi, Yusuke [1 ,2 ]
Kawamura, Masafumi [2 ]
Hato, Tai [1 ]
Harada, Masahiko [1 ]
Matsutani, Noriyuki [2 ]
Horio, Hirotoshi [1 ]
机构
[1] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Gen Thorac Surg, Bunkyo Ku, Tokyo 1138677, Japan
[2] Teikyo Univ, Sch Med, Dept Gen Thorac Surg, Itabashi Ku, Tokyo 173, Japan
关键词
PREOPERATIVE INFLAMMATORY MARKERS; NEUTROPHIL/LYMPHOCYTE RATIO; POOR-PROGNOSIS; CANCER; SURVIVAL; EXPRESSION; VALIDATION; PREDICTOR; CARCINOMA; COHORT;
D O I
10.1007/s00268-015-3275-2
中图分类号
R61 [外科手术学];
学科分类号
摘要
The neutrophil-lymphocyte ratio (NLR) is a simple and low-cost index that may be a benchmark for systemic inflammatory response and antitumor immunity. The goal of the study was to investigate the prognostic value of preoperative NLR in patients with lung adenocarcinoma after complete resection. The subjects were 361 consecutive patients with lung adenocarcinoma who underwent complete resection between 2000 and 2009. Perioperative clinical and laboratory data were evaluated retrospectively. The cohort was divided using the cut-off value for preoperative NLR identified in receiver operating characteristic analysis. Correlations of NLR with clinicopathological characteristics and prognosis were examined. A high NLR was significantly correlated with a smoking history > 10 pack-years (p = 0.023), pathological stage II or III (p < 0.001), lymphatic invasion (p = 0.003), and pleural invasion (p = 0.039). In univariate analysis, the high NLR group had significantly lower 5-year overall survival (86.0 vs. 77.1 %, p < 0.001) and 5-year recurrence-free survival (75.1 vs. 59.9 %, p < 0.001). Multivariate analysis showed that NLR was an independent prognostic factor (hazard ratio 1.822, 95 % confidence interval 1.133-2.931, p = 0.013). These results show that preoperative NLR is an independent prognostic factor in patients with lung adenocarcinoma after complete resection. NLR may reflect host immunity and systemic inflammation that facilitates tumor growth.
引用
收藏
页码:365 / 372
页数:8
相关论文
共 41 条
  • [1] Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status
    An, She-Juan
    Chen, Zhi-Hong
    Su, Jian
    Zhang, Xu-Chao
    Zhong, Wen-Zhao
    Yang, Jin-Ji
    Zhou, Qing
    Yang, Xue-Ning
    Huang, Ling
    Guan, Ji-Lin
    Nie, Qiang
    Yan, Hong-Hong
    Mok, Tony S.
    Wu, Yi-Long
    [J]. PLOS ONE, 2012, 7 (06):
  • [2] [Anonymous], 2018, ANTI-CANCER DRUG, DOI [DOI 10.3322/caac.20115, DOI 10.1097/CAD.0000000000000617]
  • [3] [Anonymous], WHO CLASSIFICATION T
  • [4] A Japanese lung cancer registry study - Prognosis of 13,010 resected lung cancers
    Asamura, Hisao
    Goya, Tomoyuki
    Koshiishi, Yoshihiko
    Sohara, Yasunori
    Eguchi, Kenji
    Mori, Masaki
    Nakanishi, Yohichi
    Tsuchiya, Ryosuke
    Shimokata, Kaoru
    Inoue, Hiroshi
    Nitkiwa, Toshihiro
    Miyaoka, Etsuo
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (01) : 46 - 52
  • [5] Ben QW, 2015, PANCREAS, V44, P471, DOI 10.1097/MPA.0000000000000271
  • [6] Adenocarcinoma Contains More Immune Tolerance Regulatory T-cell Lymphocytes (Versus Squamous Carcinoma) in Non-small-Cell Lung Cancer
    Black, Candice C.
    Turk, Mary Jo
    Dragnev, Konstantin
    Rigas, James R.
    [J]. LUNG, 2013, 191 (03) : 265 - 270
  • [7] PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
    D'Incecco, A.
    Andreozzi, M.
    Ludovini, V.
    Rossi, E.
    Capodanno, A.
    Landi, L.
    Tibaldi, C.
    Minuti, G.
    Salvini, J.
    Coppi, E.
    Chella, A.
    Fontanini, G.
    Filice, M. E.
    Tornillo, L.
    Incensati, R. M.
    Sani, S.
    Crino, L.
    Terracciano, L.
    Cappuzzo, F.
    [J]. BRITISH JOURNAL OF CANCER, 2015, 112 (01) : 95 - 102
  • [8] Non-Small Cell Lung Cancer, Version 2.2013 Featured Updates to the NCCN Guidelines
    Ettinger, David S.
    Akerley, Wallace
    Borghaei, Hossein
    Chang, Andrew C.
    Cheney, Richard T.
    Chirieac, Lucian R.
    D'Amico, Thomas A.
    Demmy, Todd L.
    Govindan, Ramaswamy
    Grannis, Frederic W., Jr.
    Grant, Stefan C.
    Horn, Leora
    Jahan, Thierry M.
    Komaki, Ritsuko
    Kong, Feng-Ming
    Kris, Mark G.
    Krug, Lee M.
    Lackner, Rudy P.
    Lennes, Inga T.
    Loo, Billy W., Jr.
    Martins, Renato
    Otterson, Gregory A.
    Patel, Jyoti D.
    Pinder-Schenck, Mary C.
    Pisters, Katherine M.
    Reckamp, Karen
    Riely, Gregory J.
    Rohren, Eric
    Shapiro, Theresa A.
    Swanson, Scott J.
    Tauer, Kurt
    Wood, Douglas E.
    Yang, Stephen C.
    Gregory, Kristina
    Hughes, Miranda
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (06): : 645 - 653
  • [9] Gökhan S, 2013, EUR REV MED PHARMACO, V17, P653
  • [10] The IASLC lung cancer staging project: Proposals for the revision of he TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours
    Goldstraw, Peter
    Crowley, John
    Chansky, Kari
    Giroux, Dorothy J.
    Groome, Patti A.
    Rami-Porta, Ramon
    Postmus, Pieter E.
    Rusch, Valerie
    Sobin, Leslie
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : 706 - 714